Treatment Cessation in Chronic Myeloid Leukemia: Evidence and
Uncertainties

J 2025

Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties

MAYER, Jiří

Základní údaje

Originální název

Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties

Autoři

MAYER, Jiří

Vydání

Hematological Oncology, Hoboken, WILEY-BLACKWELL, 2025, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143852

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

chronic myeloid leukemia; treatment cessation; treatment-free remission; withdrawal syndrome

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 3. 2026 13:25, Mgr. Tereza Miškechová

Anotace

V originále

Testing to discontinue imatinib already started some years after the advent of this new CML therapy. Since that time, despite many trials and studies in this field, there are still significant gaps, and many fundamental questions remain unanswered. Probably the most intriguing is the persistence of minimal residual disease, which does not lead to disease recurrence in all patients. Nevertheless, today's understanding enables TKI to be safely discontinued in eligible patients outside clinical trials. Notwithstanding, TKI cessation still has to be considered and indicated with caution, taking into account several important viewpoints, like: (i) why stop the therapy in a particular patient, and are all the eligible patients willing to cease the treatment? (ii) Will all the TKI-related side effects relieve upon stopping? (iii) are there any side effects after discontinuing treatment? This review covers extensively all aspects of treatment cessation, like history, theoretical background, eligible patients, monitoring after treatment discontinuation, trigger for retreatment, therapy restart, predictive factors for successful therapy cessation, immunological aspects, potential complications of TKI withdrawal, late molecular relapses, blast crisis development, kinetics of preexisting TKI-related side effects and laboratory values, and quality of life upon treatment cessation. The art of treatment cessation is to select the best candidate based on many diverse facts and information, and follow the patient in the most rational way with smartly anticipating the potential risks and side effects.

Citovat

MAYER, Jiří. Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties. Hematological Oncology. Hoboken: WILEY-BLACKWELL, 2025, roč. 43, č. 6, s. 1-22. ISSN 0278-0232. Dostupné z: https://doi.org/10.1002/hon.70155.

@article{2558057,
   author = {Mayer, Jiří},
   article_location = {Hoboken},
   article_number = {6},
   doi = {https://doi.org/10.1002/hon.70155},
   keywords = {chronic myeloid leukemia; treatment cessation; treatment-free remission; withdrawal syndrome},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hon.70155},
   volume = {43},
   year = {2025}
}

TY  - JOUR
ID  - 2558057
AU  - Mayer, Jiří
PY  - 2025
TI  - Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties
JF  - Hematological Oncology
VL  - 43
IS  - 6
SP  - 1-22
EP  - 1-22
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - chronic myeloid leukemia
KW  - treatment cessation
KW  - treatment-free remission
KW  - withdrawal syndrome
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hon.70155
N2  - Testing to discontinue imatinib already started some years after the advent of this new CML therapy. Since that time, despite many trials and studies in this field, there are still significant gaps, and many fundamental questions remain unanswered. Probably the most intriguing is the persistence of minimal residual disease, which does not lead to disease recurrence in all patients. Nevertheless, today's understanding enables TKI to be safely discontinued in eligible patients outside clinical trials. Notwithstanding, TKI cessation still has to be considered and indicated with caution, taking into account several important viewpoints, like: (i) why stop the therapy in a particular patient, and are all the eligible patients willing to cease the treatment? (ii) Will all the TKI-related side effects relieve upon stopping? (iii) are there any side effects after discontinuing treatment? This review covers extensively all aspects of treatment cessation, like history, theoretical background, eligible patients, monitoring after treatment discontinuation, trigger for retreatment, therapy restart, predictive factors for successful therapy cessation, immunological aspects, potential complications of TKI withdrawal, late molecular relapses, blast crisis development, kinetics of preexisting TKI-related side effects and laboratory values, and quality of life upon treatment cessation. The art of treatment cessation is to select the best candidate based on many diverse facts and information, and follow the patient in the most rational way with smartly anticipating the potential risks and side effects.
ER  -

MAYER, Jiří. Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties. \textit{Hematological Oncology}. Hoboken: WILEY-BLACKWELL, 2025, roč.~43, č.~6, s.~1-22. ISSN~0278-0232. Dostupné z: https://doi.org/10.1002/hon.70155.

Přehled o publikaci